BPMC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BPMC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Blueprint Medicines's EBIT per Share for the three months ended in Dec. 2023 was $-2.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.05.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Blueprint Medicines's EBIT per Share or its related term are showing as below:
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Blueprint Medicines was -5.50% per year. The lowest was -42.00% per year. And the median was -21.20% per year.
Blueprint Medicines's EBIT for the three months ended in Dec. 2023 was $-123.5 Mil.
The historical data trend for Blueprint Medicines's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blueprint Medicines Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBIT per Share | Get a 7-Day Free Trial | -7.56 | 5.50 | -10.84 | -8.86 | -7.96 |
Blueprint Medicines Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EBIT per Share | Get a 7-Day Free Trial | -2.43 | -2.04 | -2.00 | -1.98 | -2.03 |
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Blueprint Medicines's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as
EBIT per Share | (A: Dec. 2023 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -482.021 | / | 60.558 |
= | -7.96 |
Blueprint Medicines's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as
EBIT per Share | (Q: Dec. 2023 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | -123.462 | / | 60.897 |
= | -2.03 |
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blueprint Medicines (NAS:BPMC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Thank you for viewing the detailed overview of Blueprint Medicines's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Ariel Hurley | officer: Principal Accounting Officer | C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Jeffrey W. Albers | director, officer: CEO & President | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Christopher K. Murray | officer: SVP, Technical Operations | C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
Fouad Namouni | officer: President, R and D | 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116 |
L. Becker Hewes | officer: Chief Medical Officer | C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139 |
Percy H. Carter | officer: Chief Scientific Officer | C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Philina Lee | officer: Chief Commercial Officer | C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6 |
Christina Rossi | officer: Chief Commercial Officer | 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139 |
Tracey L Mccain | officer: EVP and Chief Legal Officer | C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
Michael Landsittel | officer: Principal FAO | BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Debra Durso-bumpus | officer: Chief People Officer | C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Kate Haviland | officer: Chief Business Officer | BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139 |
John Tsai | director | BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
George Demetri | director | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 12-04-2023
By GuruFocus Research • 10-26-2023
By GuruFocus Research • 11-14-2023
By PRNewswire • 07-05-2023
By GuruFocus Research • 11-04-2023
By PRNewswire • 08-02-2023
By PRNewswire • 12-09-2023
By PRNewswire • 10-26-2023
By PRNewswire PRNewswire • 06-05-2023
By PRNewswire • 10-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.